604 results about "Cell injury" patented technology

A method and kit for detecting the immediate or early onset of renal disease and injury, including renal tubular cell injury, utilizing NGAL as an immediate or early on-set biomarker in a sample of blood serum. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the blood serum following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctuate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the serum is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.

Monoclonal antibodies that bind specifically to Claudin 3 expressed on cell surface are provided. The antibodies of the present invention are useful for diagnosis of cancers that have enhanced expression of Claudin 3, such as ovarian cancer, prostate cancer, breast cancer, uterine cancer, liver cancer, lung cancer, pancreatic cancer, stomach cancer, bladder cancer, and colon cancer. The present invention provides monoclonal antibodies showing cytotoxic effects against cells of these cancers. Methods for inducing cell injury in Claudin 3-expressing cells and methods for suppressing proliferation of Claudin 3-expressing cells by contacting Claudin 3-expressing cells with a Claudin 3-binding antibody are disclosed. The present application also discloses methods for diagnosis or treatment of cancers.

The invention relates to a method for preparing human umbilical cord mesenchymal stem cells, which comprises the steps of collection, transportation, handover, separation, freezing, recovering, primary culture and subculture of umbilical cords. The method has simple process, ensures low production cost, good freezing effect, little cell damage, low toxic side effect and no harm to human body and reduces the residual of the freezing protection liquid in the recovered cells of tissue blocks; and the prepared mesenchymal stem cells can be applied to the clinical treatment of various diseases.

Methods of assessing the ongoing kidney status in a subject afflicted with chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in fluid samples over time is disclosed. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine and serum as a result of chronic renal tubule cell injury. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.

In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

A high frequency alternating current medical device and method of using such is disclosed. High frequency alternating current medical device comprises a power source, an electric field generator, a self-limiting conductive material electrical component, at least one probe or needle-type projection, and at least two conductive segments located on probe or needle-type projection. At least two conductive segments are electrically connected to electric field generator so that an electric field is created between conductive segments, which induces an electrical current, which generates heat, and causes a certain desired precise cell injury. Self-limiting conductive material electrical component allows such precise cell injury because it limits electrical current through target tissue. Invention may be used in medical, dental, or veterinary applications. Exemplary embodiments include cosmetic applications, treatment of wrinkles, remodeling of subcutaneous tissue, treatment of muscle spasms, and others. Medical device can be small, hand-held, and easily manipulated to perform surgery.

In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject suffering from, or at risk for developing a thrombotic microangiopathy (TMA). The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact.

In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

The invention discloses a construction method of an umbilical cord mesenchyma stem cell bank utilizing newborn umbilical cords as resources, aiming at causing the steps to be less and the operation to be simpler and easier when constructing the umbilical cord mesenchyma stem cell bank. The invention comprises the following steps: (1), taking a human umbilical cord for detection, using a buffer solution to wash and remove residual blood, shearing to pieces, thus obtaining human umbilical cord tissue; (2), adding collagenase for digestion; (3), adding the buffer solution for diluting the digested tissue followed by organizing, mixing evenly and centrifuging; (4), abandoning the supernatant, adding the buffer solution for heavy suspension precipitation, screening, collecting filtrate and centrifuging, and repeating twice to obtain the human umbilical cord mesenchyma stem cell; (5), saving the obtained human umbilical cord mesenchyma stem cell in liquid nitrogen according to ABO/Rh parting and HLA parting thereof, establishing a cell information archive for retrieval, thus constructing the human umbilical cord mesenchyma stem cell bank. Compared with the existing method, the invention is more fast and convenient, and has less damage to the cell.

A method for prophylactically treating a gastrointestinal disorder or skin ailment in a mammal through the administration of an enhanced bioactive agent composition comprising a bioactive agent and at least one of a soy product, licorice product, or sodium bicarbonate (depending upon the indication to be treated) is provided according to the invention. The bioactive agent preferably is bovine colostrum. The effective amount of enhanced bioactive agent composition to be used will depend upon such factors as the age and weight of the mammal, the bioactivity level of the bioactive agent, the gastrointestinal disorder or skin ailment at issue, and whether treatment of existing symptoms of the gastrointestinal disorder or skin ailment, or prevention of the onset of such symptoms is desired. A medicament comprising an enhanced bioactive agent composition for prophylactically treating a gastrointestinal disorder or skin ailment in a mammal is also provided according to the invention.

The present invention provides for a method for stimulating the proliferation of pluripotential stem cells in a mammal comprising administration of pregnancy related compounds more particularly human chorionic gonadotropin, leutenizing hormone or prolactin. The present invention further provides for a method of treatment of tissues or organs experiencing cellular damage, injury or disease.

It is intended to provide preventives/remedies for graft-versus-host disease and/or rejection in organ or bone marrow transplantation, rheumatoid arthritis, autoimmune diseases, allergic diseases, ischemic cerebral cell injury, myocardial infarction, chronic nephritis and arteriosclerosis. The above object can be achieved by preventives/remedies for graft-versus-host disease and/or rejection in organ or bone marrow transplantation, rheumatoid arthritis, autoimmune diseases, allergic diseases, ischemic cerebral cell injury, myocardial infarction, chronic nephritis and arteriosclerosis characterized by containing a specific compound having a CCR (CC chemokine receptor) antagonism.

The present invention relates to methods and immunonutritional compositions for preventing the impairment of the immune function during anti-cancer therapy, thereby attaining a better efficacy of the treatment. More particularly, the present invention relates to methods and immunonutritional compositions that can transiently preventing or moderating, bone marrow paralysis or neutropenia of a subject undergoing anti-cancer therapy-induced apoptosis or necrosis or other cell damage such that the innate and adaptive immune functions and normal physiology of the bone marrow are preserved, at least in part, which, in turn, lead to (i) a better tolerance and increased efficacy to anti-cancer therapy; (ii) transient augmentation or enhancement of immunocompetence of the immune cell; and (iii) optimization of the effects of and increase of immunocompetence of the immune cell weakened by anti-cancer therapy.

The invention relates to the technical field of cytobiology, and particularly relates to a hemopoietic stem cell cryopreserving solution, and a hemopoietic stem cell cryopreserving method. The cryopreserving solution includes following raw materials by weight: 10-20 mL of dimethyl sulfoxide, 6-10 g of hydroxyethyl starch, 4-8 mL of a cell culture medium, 6-10 mL of human serum albumin, and 60-100 mL of human autologous plasma. The formula of the cryopreserving solution is simple, and the raw materials are cheap. The cryopreserving solution can effectively protect hemopoietic stem cells from freezing injuries, is high in safety and low in cell injuries, can increase the resuscitation survival rate of hemopoietic stem cells. The survival rate after resuscitation can be 96% or above, and after resuscitation, the cell viability is high, the quantity of cell proliferation is high, the cells are not liable to age, physiological functions and biological characteristics of the hemopoietic stem cells after resuscitation can be ensured, and microbe detection indexes meet requirements. The survival time of the hemopoietic stem cells is prolonged.

Inositol hexaphosphate (IP-6) is a polyphosphorylated carbohydrate with potent antioxidant activity to prevent active oxygen species-mediated mutagenesis, cell injury and carcinogenesis. IP-6 also activates DNA repair mechanisms. Sublethal radiation causes DNA damage through the formation of free radicals, reactive oxygen species, and pyrimidine crosslinks leading to cellular proliferation, cell cycle arrest and apoptosis. In the skin it results in the induction of skin cancer, premature skin aging, immuno-suppression, inflammation, and cell death. Likewise sublethal exposure to ionizing radiation as in nuclear blasts (war-time, accidental, terrorist-induced etc), cosmic radiation, etc. also causes the same spectrum of damage to the cells and the organisms with acute symptoms and eventual high risk of many cancers. IP-6 and/or inositol and their pharmaceutically acceptable salts and derivatives, including pyrophosphates and citrate derivatives, significantly counteract the harmful effects of radiation, affecting cell cycle progression in a protective manner (more cells in the protective GI phase) as well as decreasing apoptosis and caspase-3 activation. Various salts of IP-6 are used with comparable efficacy and the combination of IP-6+inositol affords the best protection against radiation-induced cell injury. Thus IP-6 and inositol are effective agents for protection against nuclear, solar and other radiation injuries.

This invention concerns novel compositions and methods for for the protection of organs and cells from damage caused by activated lymphocytes, NK-cells and NK-like cells, more particularly compositions and methods for the protection of vascular endothelial cells from immune system-mediated damage.

The invention provides a novel menstrual blood-derived mesenchymal stem cell separation method, belonging to the field of methods for separating stem cells from menstrual blood. In order to solve the problems of long centrifugal time, relatively serious cell injury, low cell yield and the like existing in a lymph separating medium method in the traditional method, the invention provides the novel menstrual blood-derived mesenchymal stem cell separation method comprising the steps of with source-wide menstrual blood as a material, storing by using a special preserving fluid in a collecting process; then, carrying out primary separation by using a density gradient centrifugation method of a lymphocyte separation tube, and optimizing the centrifugal time and centrifugal rotating speed in separation; and next, carrying out secondary separation according to the wall attachment growth characteristic of the stem cells, simultaneously separating and amplifying the stem cells, and maintaining the activity of the stem cells to the maximum extent in the separation process. The obtained menstrual blood-derived mesenchymal stem cell is high in purity, quantity and application value. The novel menstrual blood-derived mesenchymal stem cell separation method is simple in operation and low in cost.

The present invention relates to a method for processing human placental cell sample, a human placental cell sample obtained according to said method for processing human placental cell sample, a human placental cell bank, a method for banking human placental cells, a method for searching human placental cell sample in said human placental cell bank according to the present invention, a method for preparing human cord blood serum, use of human placental cells obtained by said method for processing human placental cell sample or human placental cell bank established by said method for banking human placental cells in treating human dysfunction and diseases due to cell injury or cell malfunction, as well as a method for treating human dysfunction and diseases due to cell injury or cell malfunction.